Use of isoniazid for latent tuberculosis infection in a public health clinic

American Journal of Respiratory and Critical Care Medicine

Volumn 168, Issue 4, 2003, Pages 443-447

  LoBue, Philip A ^a   Moser, Kathleen S ^b  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b NONE

Author keywords

Adherence; Adverse effects; Hepatotoxicity; Isoniazid; Latent tuberculosis

Indexed keywords

ISONIAZID;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; CHILD; DATA BASE; DRUG SAFETY; ETHNOLOGY; FEMALE; HEADACHE; HEALTH CENTER; HOMELESSNESS; HOSPITALIZATION; HUMAN; INCIDENCE; INFANT; LIVER INJURY; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; NAUSEA AND VOMITING; PARESTHESIA; PRIORITY JOURNAL; PRURITUS; RASH; TREATMENT OUTCOME; TUBERCULOSIS; VERTIGO;

ADOLESCENT; ADULT; AGE FACTORS; AGED; ALCOHOLISM; ANTITUBERCULAR AGENTS; EMIGRATION AND IMMIGRATION; ETHNIC GROUPS; FEMALE; HISPANIC AMERICANS; HOMELESS PERSONS; HUMANS; ISONIAZID; LIVER DISEASES; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PUBLIC HEALTH; SAFETY; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY;

EID: 0041827156     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/rccm.200303-390OC     Document Type: Article

References (18)

1. Ferebee SH. Controlled chemoprophylaxis trials in tuberculosis: a general review. Adv Tuberc Res 1970;17:28-106.
2. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUATL trial: International Union Against Tuberculosis Committee on Prophylaxis. Bull World Health Organ 1982;60:555-564.
3. Comstock GW. How much isoniazid is needed for the prevention of tuberculosis among immunocompetent adults? Int J Tuberc Lung Dis 1999;3:847-850.
4. Ferebee SH, Mount FW. Tuberculosis morbidity in a controlled trial of the prophylactic use of isoniazid among household contacts. Am Rev Respir Dis 1962;85:490-521.
5. Garibaldi RA, Drusin RE, Ferebee SH, Gregg MB. Isoniazid-associated hepatotoxicity: report of an outbreak. Am Rev Respir Dis 1972;106:357-365.
6. Kopanoff DE, Snider DE, Caras GJ. Isoniazid-related hepatotoxicity: a US Public Health Service cooperative surveillance study. Am Rev Respir Dis 1978;117:991-1001.
7. Steele MA, Burk RF, DesPrez RM. Toxic hepatotoxicity with isoniazid and rifampin: a meta-analysis. Chest 1991;99:465-471.
8. Nolan CM, Goldberg SV, Buskin SE. Hepatotoxicity associated with isoniazid preventive therapy: a seven year survey from a public health clinic. JAMA 1999;281:1014-1018.
9. Targeted tuberculin testing and treatment of latent tuberculosis infection: American Thoracic Society and Centers for Disease Control and Prevention. Am J Respir Crit Care Med 2000:161:S221-S247.
10. Jasmer RM, Saukonnen JJ, Blumberg HM, Daley CL, Bernardo J, Vittinghoff EV, King MD, Kawamura LM, Hopewell PC. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial. Ann Intern Med 2002;137:640-647.
11. Halsey NA, Coberly JS, Desormeaux J, Losikoff P, Atkinson J, Moulton LH, Contave M, Johnson M, Davis H, Geiter L, et al. Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection. Lancet 1998;351:786-792.
12. Gordin FM, Chaisson RE, Marts JP, Miller C, Garcia M, Hafner R, Valdespino JL, Coberly J, Schechter M, Klukowicz AJ, et al. Rifampin and pyrazinamide vs. isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. JAMA 2000;283:1445-1450.
13. Lambert L. Update: fatal and severe liver injuries associated with rifampin and pyrazinamide treatment for latent tuberculosis infection. Morb Mortal Wkly Rep 2002;51:998-999.
14. Stout JE, Engemann JJ, Cheng AC, Fortenberry ER, Hamilton CD. Safety of 2 months of rifampin and pyrazinamide for treatment of latent tuberculosis. Am J Respir Crit Care Med 2003;167:824-827.
15. Burman WJ, Reves RR. Hepatotoxicity from rifampin and pyrazinamide: lessons for policy makers and messages for care providers. Am J Respir Crit Care Med 2001;164:1112-1113.
16. Jasmer RM, Snyder DC, Chin DP, Hopewell PC, Cuthbert SS, Antonio Paz E, Daley CL. Twelve months of isoniazid compared with four months of isoniazid and rifampin for persons with radiographic evidence of previous tuberculosis: an outcome and cost-effectiveness analysis. Am J Respir Crit Care Med 2000;162:1648-1652.
17. LoBue PA, Moser K. Factors associated with completion of latent tuberculosis treatment [abstract]. Am J Respir Crit Care Med 2002;163:A713.
18. Treatment of tuberculosis and tuberculosis infection in adults and children: American Thoracic Society. Am J Respir Crit Care Med 1994;149:1359-1374.